TRK Fusion Cancer diagnosis is based on the genomic tests that can detect NTRK gene fusions, which is an underlying cause of TRK fusion cancer. The results of genomic tests can help identify certain biomarkers for a tumor and make it possible to match the patient to the appropriate treatment option.
TRK inhibitors Treatment has demonstrated dramatic and durable tumor-agnostic efficacy in TRK fusion-positive cancer. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rates (>75%), regardless of tumour histology.
Learn for more information about TRK Fusion Cancer Market
In 2019, Rozlytrek (Roche) became the third tumor agonist product to be approved. As opposed to Vitrakvi, Rozlytrek won approval for tumor-specific indication in ROS1 positive NSCLC in addition to the tumor agonist indication, solid tumors with NTRK gene fusion. So far, two first-generation molecules (entrectinib and larotrectinib) have received FDA therapeutic approval for the treatment of NTRK fusion-positive tumors and the latter recently gained EMA approval as well.
The compact and rigid three-dimensional structure enables repotrectinib to precisely and efficiently bind deep into the ATP binding pocket of the kinase, and potentially circumvent the steric interference that results in resistance to bulkier kinase inhibitors, especially the solvent-front and gatekeeper mutations of ROS1, TRK, and ALK kinases.
It is being evaluated by Turning Point Therapeutics in Phase I/II clinical development for the treatment of advanced NSCLC (ROS1, Solid Tumors (NTRK) and Pediatric Advanced Solid Tumors.
Source:- TRK Fusion Cancer Market Share
